Purpose As a complete consequence of the questionable risk-to-benefit proportion of adjuvant therapies, stage II melanoma happens to be managed by observation because available clinicopathologic variables cannot identify the 20% to 60% of such sufferers more likely to develop metastatic disease. forecasted by ATF2 ln(non-nuclear/nuclear AQUA rating proportion) greater than C0.052, p21WAF1 nuclear area AQUA… Continue reading Purpose As a complete consequence of the questionable risk-to-benefit proportion of